According to our latest study on “Pharmaceutical Excipients Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Clinical Indication, Functionality, Application, End User,” the market is expected to grow from US$ 7,825.38 million in 2021 to US$ 12,245.04 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2022 to 2028. The growing generics market and increasing product launches are boosting the growth of the pharmaceutical excipients market. However, the cost and time-intensive drug development process with pharmaceutical excipients are hampering the market growth.
Get PDF Brochure with Table of Contents and Important Figures at: https://www.theinsightpartners.com/sample/TIPRE00003534/
The pharmaceutical excipients market is characterized by the presence of large and small market players. A few product launches related to pharmaceutical excipients are mentioned below:
- In October 2022, Rouqette, a pharmaceutical and nutraceutical excipients provider, launched two next-generation mannitol products—PEARLITOL CR-H and PEARLITOL 200 GT— for direct compression. These excipients have been specially formulated to overcome the unique drug formulation challenges in the pharmaceutical spaces, which helps the manufacturers optimize direct compression processes and expand into application areas such as mini tabs and controlled-release tablets.
- In March 2022, Lubrizol Life Science Health launched Apisolex, a novel solubility-enhancing excipient for parenteral drug products. With the ability to improve solubility by up to 50,000-fold and support high drug loading, Apisolex excipient provides access to new and improved parenteral drug products. This is especially relevant in oncology, as direct injection of drugs into the bloodstream ensures higher bioavailability and lower patient variability compared to oral delivery.
- In November 2021, Gattefosse, a France-based company that designs and produces pharmaceutical excipients, launched three new pharmaceutical excipients—Labrefac MC60, Gelucire 59/14, and Emulfree Duo. Labrefac MC60 and Gelucire 59/14 excipients are used for the oral administration route drugs, whereas Emulfree Duo is used for the topical administration route drugs.
- In August 2021, SPI Pharma, a US-based company, introduced Ultrabust, an excipient platform for flash orally disintegrating tablets (ODTs). The use of Ultrabust excipient in an ODT formulation facilitates the disintegration of the tablet in under 10 seconds.
- In April 2021, DFE Pharma, the pharmaceutical excipient solution provider, launched its new product line, BioHale, a solution for biopharmaceutical manufacturers. With the launch of BioHale Sucrose, DFE Pharma offers exceptional market purity and low endotoxin excipient to be used in the formulation.
The active participation of market players in product innovation and development leading to the increase in product launches fuel the growth of the pharmaceutical excipients market.
Based on end user, the pharmaceutical excipients is segmented into biopharma industries, pharma industries, animal health, and others. The pharma industries segment is likely to hold the largest share of the market in 2022; however, the biopharma industries is expected to register the highest CAGR from 2022 to 2028.
Impact of COVID-19 Pandemic on Pharmaceutical Excipients
The global supply chain of medicines was under pressure during the COVID-19 pandemic because of a deficit of raw materials such as active pharmaceutical ingredients (APIs) and excipients. According to the Council on Foreign Relations, a large share of the medicines sold in the US are produced in China and India, while these two countries meet almost 80% of the US API demand. As one of the world’s largest producers of generic medicines (producing 20% of global generics supply), India imports almost 70% of its APIs from China; therefore, disruption in its supply chain has resulted in drug supply shortages. In the likely and best-case scenarios, the effects of disruptions on pharmaceutical production and consequently on excipient demand caused by lockdowns and travel and transport bans across various countries, especially in the US, are relatively short-term. There is a rise in the discovery of clinical drugs for COVID-19, which caused growth in the pharmaceutical excipient market. However, the supply disruptions due to extended lockdowns in various countries was substantially impacted oral solid dosage drug manufacturing and, in turn, significantly impacted the demand growth of excipients worldwide.
JRS PHARMA GmbH & Co KG, Roquette Freres SA, BASF SE, Evonik Industries AG, AshLand Inc, Archer-Daniels-Midland Co, The Dow Chemical Co, The Lubrizol Corp, Avantor Inc, and MEGGLE GmbH & Co KG., Univar Solutions Inc. are a few of the key companies operating in the pharmaceutical excipients.
The report segments the pharmaceutical excipients as follows:
The pharmaceutical excipients market is analyzed based on type, clinical indication, functionality, application, end user, and geography. Based on type, the market is segmented into bioresorbable polymers, lipids, and liposome-based formulation; oleochemicals; sugars; cellulose; starches; petrochemicals; plant proteins, polyols and cyclodextrins; inorganic chemicals; and others. Based on clinical indication, the market is segmented into cancer, metabolic, infectious diseases, dental, ophthalmic, gene therapies, and others.
Based on functionality, the market is segmented into coloring agent & coating agent; sweetener & flavoring agents; suspending & viscosity agents; preservative & controlled-release; antioxidant & oil; tablet filler & diluents; binders, compression aids and granulating agents; and others. Based on application, the market is segmented into parenteral, oral formulations & tablets, capsules, liquid & injectables, physicochemical excipient-container interactions in prefilled syringes, nutraceuticals & OTC, topical, and others. Based on end user, the market is segmented into biopharma industries, pharma industries, animal health, and others.
Geographically, the pharmaceutical excipients is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of SAM).
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876